METHODS: This was a retrospective study based in electronic medical records of adult asthmatic outpatients followed at a tertiary hospital. Asthmatic patients according to GINA were assessed for a period of six years. All of them were in IC treatment. Body mass index (BMI) and spirometry were assessed after a period of six years, as well as eventual change in IC dose during that period
RESULTS: Eighty-six patients were included in the study. The mean age was 58.1 years, and 81.4% of the patients were female. All of them initially, in 2010, used budesonide ≥ 800 mcg/day. After six years of follow-up, 20 patients (23.3%) decreased their IC dose to 600 mcg/day or under (mean dose of 390 mcg/day); 66 patients (76.6%) maintained or increased their IC dose (mean dose of 1152 mcg/ day). There was no change in BMI and FEV1 during this period. FEV1 changed from 71.7% of predicted value to 68.6% at the end of evaluation.
CONCLUSIONS: Patients with severe asthma require high doses of IC to control the disease. This study observed that patients who maintained a high dose of IC for a period of 6 years showed no change in BMI and only a slight reduction of FEV1 was observed in this period